Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital
Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval....
Is There Enough Monkeypox (Mpox) Vaccine to go Around? Maybe yes, More Likely no.
Reported in Gates and Soda
As monkeypox cases continue to mount – topping 31,000 cases globally – governments of...
Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
VERU Inc. (VERU) $24. High Risk, Minimal Reward?
Pre-FDA Approval Play. The Shares Are Now in the Hands of Fast Money Traders.
You Can't Kiss all the...
What is NAC (N-Acetyl-L-Cysteine)? (Dr Eric Berg)
https://youtu.be/oPdGOrqTfhA
What is NAC good for? (and How Much to Take?)
FDA Issues Final ‘Enforcement Discretion’ Guidance on NAC.
NAC Crosses Major Hurdle With FDA. Is Bucillamine Next.
Josh Long | Aug 01, 2022
"Industry, and...
Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE
Provention (PRVB) Price Target $18.
Headline Says Downgrade, But That's Near 300% Higher From Here!
LIVE QUOTE
Althira (ATHA) $2.50, is Latest Alzheimer’s Trial Victim. Down 70%
Nearly 100 Alzheimer’s programs have failed in the past decade.
Biotech investors should study or at least become...